COMPANY

Welcome to Aprilbio

History

History of APRILBIO

2024
1
  • Participated in Biotech Showcase USA
2023
Jun
  • Participated in BIO USA
  • Participated in EASL congress in Austria
Mar
  • Mar APB-R3 clinical trial phase 1 started in Australia
  • APB-A1 clinical trial phase 1 started in USA
2022
Oct
  • Patents granted for APB-R2 and APB-R4
Aug
  • Signed contract with Yuhan for out-licensing and co-development of APB-R5
  • IND granted for APB-R3 clinical trial phase 1 in Australia
Jul
  • Listed on KOSDAQ
May
  • Preliminary examination for listing on KOSDAQ qualified
  • Registered SAFAbody™
Feb
  • Won ‘Korea new drug award’ from The 23rd Korea Technology Export Award
2021
Nov
  • Submitted application for preliminary examination of listing to Korea Exchange
Oct
  • Technology assessment passed for KOSDAQ listing
  • Out-licensed APB-A1(autoimmune disease treatment) to Denmark Lundbeck,
  • US$448m of milestone and upfront fee
  • Applied patent for SAFA in China
Sep
  • IND granted from FDA for APB-A1 clinical trial phase 1 in USA
Aug
  • Series C Investment attracted from 10 institutional investors
  • (KRW25bn capital raised in common stock)
Mar
  • KRW10bn of strategic investment attracted from Yuhan
Jan
  • Signed MOU with Yuhan for research and development
2020
Nov
  • KRW3bn of strategic investment attracted from Yuhan
  • Signed MOU with Yonsei Severance hospital
  • APB-R3 awarded The 3rd Korea Biomedicine Grand Prix
Aug
  • KRW 15bn of series B investment attracted from 7 institutional investors
Jun
  • Signed MOU with National Cancer Center for research and development
Apr
  • International patent registered for SAFA technology in 8 EU countries,
  • Canada, Japan and Mexico
Mar
  • Signed MOU with Celros Biotech for research and development
Jan
  • Moved to Tera Tower
2019
Nov
  • Signed contract with NH investment and securities for IPO bookrunning
Jul
  • SAFA tropin(outlicensed to Ahn-gook) granted IND filing
2018
Sep
  • International patent for SAFA technology registered in Japan
May
  • KRW7.5bn of series A investment attracted from 7 institutional investors
Jan
  • International patent for SAFA technology registered in USA
2017
May
  • KRW3bn of pre series A investment attracted
  • from 4 institutional investors
2016
Dec
  • Established Chuncheon Bioindustry Foundation R&D center
2015
Dec
  • KRW2.3bn of seed investment attracted from 2 institutional investors
May
  • International patent registered for SAFA technology in Korea